| Literature DB >> 34902047 |
Hessel Peters-Sengers1,2, Joe M Butler3,4, Fabrice Uhel3,4, Marcus J Schultz5,6,7,8, Marc J Bonten9,10, Olaf L Cremer11, Brendon P Scicluna3,4,12, Lonneke A van Vught3,4, Tom van der Poll3,4,13.
Abstract
PURPOSE: There is limited knowledge on how the source of infection impacts the host response to sepsis. We aimed to compare the host response in sepsis patients with a single, known source at admission (< 24 h) to the intensive care unit.Entities:
Keywords: Host response; Intensive care unit; Sepsis; Site of infection; Source of infection
Mesh:
Substances:
Year: 2021 PMID: 34902047 PMCID: PMC8667541 DOI: 10.1007/s00134-021-06574-0
Source DB: PubMed Journal: Intensive Care Med ISSN: 0342-4642 Impact factor: 17.440
Plasma biomarker cohort: baseline characteristics and outcome of patients with sepsis stratified according to source of infection
| ALL | Respiratory | Abdominal | Urinary | Cardiovascular | CNS | Skin | ||
|---|---|---|---|---|---|---|---|---|
| 621 | 334 | 159 | 44 | 41 | 18 | 25 | ||
| Age, years, mean (SD) | 60.9 (14.7) | 60.5 (15.5) | 62.1 (12.6) | 61.8 (14.8) | 61.6 (13.1) | 58.4 (15.1) | 56.7 (16.6) | 0.539 |
| Gender, female ( | 260 (41.9) | 123 (36.8)L | 72 (45.3) | 29 (65.9)H | 14 (34.1) | 6 (33.3) | 16 (64) | 0.001 |
| BMI, mean (SD) | 25.5 (6.3) | 24.6 (5.6)L | 26.1 (6.9) | 28.4 (7.2)H | 25.1 (4.5) | 25.7 (4.1) | 28.9 (9.6)H | < 0.001 |
| Race, white, | 540 (87) | 290 (86.8) | 140 (88.1) | 38 (86.4) | 35 (85.4) | 16 (88.9) | 21 (84) | 0.991 |
| Surgical admission, | 160 (25.8) | 29 (8.7)L | 87 (54.7)H | 4 (9.1)L | 22 (53.7)H | 4 (22.2) | 14 (56)H | < 0.001 |
| None | 158 (25.4) | 73 (21.9) | 52 (32.7)H | 6 (13.6) | 11 (26.8) | 10 (55.6)H | 6 (24) | 0.002 |
| Cardiovascular insufficiency | 20 (3.2) | 9 (2.7) | 6 (3.8) | 3 (6.8) | 1 (2.4) | 0 (0) | 1 (4) | 0.699 |
| Renal insufficiency | 89 (14.3) | 43 (12.9) | 23 (14.5) | 17 (38.6)H | 2 (4.9) | 1 (5.6) | 3 (12) | < 0.001 |
| Respiratory insufficiency | 51 (8.2) | 44 (13.2) | 3 (1.9)L | 2 (4.5) | 1 (2.4) | 0 (0) | 1 (4) | < 0.001 |
| Immune deficiency | 140 (22.5) | 91 (27.2)H | 25 (15.7)L | 11 (25) | 5 (12.2) | 3 (16.7) | 5 (20) | 0.041 |
| Malignancy | 146 (23.5) | 81 (24.3) | 48 (30.2)H | 6 (13.6) | 5 (12.2) | 1 (5.6) | 5 (20) | 0.026 |
| COPD | 97 (15.6) | 75 (22.5)H | 11 (6.9)L | 6 (13.6) | 4 (9.8) | 0 (0) | 1 (4) | < 0.001 |
| Diabetes | 131 (21.1) | 64 (19.2) | 34 (21.4) | 15 (34.1)H | 8 (19.5) | 1 (5.6) | 9 (36) | 0.047 |
| Charlson score (median [IQR]) | 4 [3, 6] | 4 [2, 6] | 4 [3, 6] | 4.5 [3, 5.2] | 4 [3, 5] | 3 [2, 4] | 4 [2, 5] | 0.376 |
| Gram-positive bacteria | 267 (43) | 105 (31.4)L | 91 (57.2)H | 8 (18.2)L | 32 (78)H | 10 (55.6) | 21 (84)H | < 0.001 |
| Gram-negative bacteria | 296 (47.7) | 125 (37.4)L | 111 (69.8)H | 41 (93.2)H | 4 (9.8)L | 4 (22.2) | 11 (44) | < 0.001 |
| Fungi | 49 (7.9) | 32 (9.6) | 14 (8.8) | 1 (2.3) | 1 (2.4) | 0 (0) | 1 (4) | 0.210 |
| Virus | 44 (7.1) | 41 (12.3)H | 2 (1.3)L | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | < 0.001 |
| Unknown | 112 (18) | 80 (24)H | 21 (13.2) | 2 (4.5)L | 6 (14.6) | 3 (16.7) | 0 (0) | 0.001 |
| Other | 7 (1.1) | 2 (0.6) | 3 (1.9) | 0 (0) | 1 (2.4) | 1 (5.6) | 0 (0) | 0.283 |
| Blood culture positive (%) | 156 (25.1) | 48 (14.4)L | 53 (33.3)H | 21 (47.7)H | 13 (31.7) | 9 (50)H | 12 (48)H | < 0.001 |
| mSOFA score, median [IQR]B | 7 [5, 9] | 7 [4, 9]L | 8 [6, 10]H | 8 [5, 10] | 7 [5, 8] | 3.5 [3, 5]L | 7 [6, 9] | < 0.001 |
| APACHE IV Score, mean (SD) | 82.1 (28.8) | 82 (28.9) | 83.1 (30.4) | 87.4 (26.4) | 77.5 (29.1) | 74.7 (22.1) | 79.6 (23.5) | 0.530 |
| APS, mean (SD) | 68.9 (27.3) | 68.1 (27.4) | 70.8 (28.7) | 73.7 (26) | 65.4 (27.7) | 62.6 (18.1) | 69.1 (25.2) | 0.542 |
| AKI, | 161 (25.9) | 66 (19.8)L | 57 (35.8)H | 19 (43.2)H | 9 (22) | 1 (5.6) | 9 (36) | < 0.001 |
| ARDS, | 139 (22.4) | 101 (30.2)H | 22 (13.8)L | 8 (18.2) | 4 (9.8) | 1 (5.6) | 3 (12) | < 0.001 |
| Septic shock, | 183 (29.5) | 86 (25.7) | 68 (42.8)H | 9 (20.5) | 9 (22.5) | 0 (0)L | 11 (44) | < 0.001 |
| Mechanical ventilation ( | 509 (82) | 286 (85.6)H | 130 (81.8) | 25 (56.8)L | 32 (78) | 16 (88.9) | 20 (80) | < 0.001 |
| Renal replacement therapy ( | 56 (9) | 24 (7.2) | 23 (14.5)H | 3 (6.8) | 1 (2.4) | 2 (11.1) | 3 (12) | 0.078 |
| Vasopressors ( | 378 (60.9) | 192 (57.5) | 113 (71.1)H | 24 (54.5) | 25 (61) | 3 (16.7)L | 21 (84) | < 0.001 |
| ICU LOS, days, median [IQR] | 4 [2, 9] | 5 [2, 10]H | 3 [1, 8.5] | 2 [1, 5]L | 3 [2, 5] | 5 [2, 8] | 3 [2, 9] | < 0.001 |
| Hospital LOS, days, median [IQR] | 15 [8, 32] | 14 [7, 25]L | 19 [8, 45]H | 12.5 [7.8, 23.2] | 26 [8, 42] | 18.5 [10.2, 41] | 20 [11, 41] | 0.022 |
| None | 421 (67.8) | 225 (67.4) | 102 (64.2) | 37 (84.1)H | 26 (63.4) | 13 (72.2) | 18 (72) | 0.215 |
| AKI | 114 (18.4) | 64 (19.2) | 28 (17.6) | 3 (6.8) | 13 (31.7) | 2 (11.1) | 4 (16) | 0.084 |
| ARDS | 59 (9.5) | 38 (11.4)H | 18 (11.3) | 1 (2.3) | 1 (2.4) | 0 (0) | 1 (4) | 0.081 |
| ICU-acquired infection | 60 (9.7) | 32 (9.6) | 18 (11.3) | 3 (6.8) | 4 (9.8) | 2 (11.1) | 1 (4) | 0.866 |
| ICU | 116 (18.7) | 64 (19.2) | 31 (19.5) | 6 (13.6) | 12 (29.3) | 0 (0) | 3 (12) | 0.119 |
| Hospital | 193 (31.1) | 104 (31.1) | 52 (32.7) | 12 (27.3) | 15 (36.6) | 5 (27.8) | 5 (20) | 0.762 |
| 30 days | 171 (27.5) | 98 (29.3) | 46 (28.9) | 9 (20.5) | 11 (26.8) | 2 (11.1) | 5 (20) | 0.421 |
| 90 days | 240 (38.6) | 133 (39.8) | 64 (40.3) | 13 (29.5) | 19 (46.3) | 6 (33.3) | 5 (20) | 0.235 |
| 1 year | 306 (49.3) | 174 (52.1) | 78 (49.1) | 18 (40.9) | 22 (53.7) | 7 (38.9) | 7 (28) | 0.161 |
Data presented as median [interquartile range], or n (%). Continuous variables were compared using the analysis of variance test or Kruskal–Wallis rank-sum test when appropriate, resulting in overall p value. Associations between categorical variables were tested using the Fisher’s exact test, resulting in overall p value
CNS central nervous system, APS acute physiology score, ARDS acute respiratory distress syndrome, AKI acute kidney injury, APACHE acute physiology and chronic health evaluation, ICU intensive care unit, SOFA sequential organ failure assessment
HIf significantly higher than the grand mean (mean of means of sources) of the plasma biomarker cohort
LIf significantly lower than the grand mean (mean of means of sources) of the plasma biomarker cohort
AIn 100 patients (16.1%) more than one cultured organism was assigned as causative
BmSOFA modified sequential organ failure assessment (excluding central nervous system component)
CComplications were defined as ICU-acquired when diagnosed more than 48 h after admission to the ICU
Fig. 130-day mortality incidence (%) among sepsis patients with different sources of infection; p values calculated by type-III overall Wald test. Data are presented as bars with 95% confidence bands. Adjusted model included age, sex, ethnicity, BMI, Charlson comorbidity score (without age), admission type, hospital site, blood culture positivity, type of causative pathogen, mSOFA score, Acute Physiology Score and shock
Pairwise comparison of 30-day mortality among sepsis patients with differences sources of infection
| Unadjusted | Respiratory | Abdominal | Urinary | Cardiovascular | CNS | Skin |
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Respiratory (ref) | na | 0.89 (0.66–1.2) | 0.53 (0.33–0.85)* | 0.9 (0.51–1.57) | 0.67 (0.37–1.2) | 0.86 (0.51–1.46) |
| Abdominal (ref) | 1.12 (0.83–1.52) | na | 0.6 (0.36–0.99)* | 1.01 (0.56–1.84) | 0.75 (0.4–1.41) | 0.97 (0.55–1.71) |
| Urinary (ref) | 1.88 (1.17–3.02)* | 1.67 (1–2.81)* | na | 1.69 (0.84–3.41) | 1.26 (0.61–2.6) | 1.62 (0.82–3.19) |
| Cardiovascular (ref) | 1.11 (0.64–1.95) | 0.99 (0.54–1.8) | 0.59 (0.29–1.19) | na | 0.74 (0.34–1.63) | 0.96 (0.46–2.01) |
| CNS (ref) | 1.5 (0.83–2.70 | 1.33 (0.71–2.49) | 0.8 (0.38–1.64) | 1.34 (0.61–2.94) | na | 1.29 (0.6–2.76) |
| Skin (ref) | 1.16 (0.68–1.97) | 1.03 (0.58–1.83) | 0.62 (0.31–1.22) | 1.04 (0.5–2.19) | 0.78 (0.36–1.67) | na |
| Adjusted | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Respiratory (ref) | na | 0.68 (0.47–0.98)* | 0.46 (0.27–0.78)* | 0.95 (0.51–1.77) | 1.12 (0.59–2.14) | 0.81 (0.44–1.49) |
| Abdominal (ref) | 1.47 (1.02–2.11)* | na | 0.68 (0.38–1.21) | 1.33 (0.69–2.54) | 1.64 (0.81–3.32) | 1.14 (0.6–2.14) |
| Urinary (ref) | 2.17 (1.28–3.69)* | 1.48 (0.83–2.66) | na | 2.12 (0.98–4.55) | 2.43 (1.09–5.44)* | 1.81 (0.86–3.83) |
| Cardiovascular (ref) | 1.05 (0.56–1.96) | 0.75 (0.39–1.44) | 0.47 (0.22–1.02) | na | 1.22 (0.52–2.85) | 0.86 (0.38–1.93) |
| CNS (ref) | 0.89 (0.47–1.71) | 0.61 (0.3–1.23) | 0.41 (0.18–0.92)* | 0.82 (0.35–1.91) | na | 0.7 (0.3–1.62) |
| Skin (ref) | 1.23 (0.67–2.25) | 0.88 (0.47–1.66) | 0.55 (0.26–1.17) | 1.17 (0.52–2.64) | 1.43 (0.62–3.30) | na |
Only known single sources of infection shown (see eTable 5 for unknown, other and mixed sources). Model adjusted for age, sex, BMI, Charlson comorbidity score (without age), admission type, hospital site, causative pathogen, blood culture positive, the Acute Physiology Score, mSOFA score, and septic shock
OR odds ratio, CI confidence interval, ref reference category, na not applicable
*p < 0.05 versus the reference category
Fig. 2Host response biomarkers in patients with sepsis on admission stratified according to the source of infection. Biological parameters are classified as A inflammatory responses, B endothelial cell activation, and C coagulation activation biomarkers. Data are presented as principal component analysis (PCA) plots (far left side of each row), and box and whiskers (with dotted lines in box plots representing median values obtained in 27 healthy age-matched healthy subjects). Ellipse circles of infection groups in PCA plots are drawn around patient data points (not shown here for clarity), wherein the centroid is the barycenter of the patient data points belonging to the same source of infection; arrows in PCA plots indicate direction of correlation of plasma markers with loadings of PCA components. p values in box plots represent type-III Wald tests for the source of infection groups derived from linear regression models, wherein the adjusted model included age, sex, ethnicity, BMI, Charlson comorbidity score (without age), admission type, hospital site, blood culture positivity, type of causative pathogen, mSOFA score, Acute Physiology Score and shock. ANG angiopoietin, aPTT activated partial thromboplastin time, IL interleukin, MMP matrix metalloproteinase, PT prothrombin time, sE-Selectin soluble E-selectin, sICAM soluble intercellular adhesion molecule
Fig. 3Blood transcriptomics response in patients with sepsis on admission stratified according to the source of infection. A Venn–Euler diagram illustrating the shared and distinct leukocyte transcriptional responses between source of infection groups relative to health (with differential expressed genes according to high effect size > 0.8 with Hedges g). Number of overlapping genes are shown if above 65. B Pairwise comparison of source of infection groups showing common transcriptional response (with differential expressed genes according to medium effect size > 0.4 with Hedges g). C Pathway analysis of the common response to sepsis (4126 genes common to all sources) relative to health. Canonical signaling sub-pathways were grouped into their parent pathway according to Reactome pathway database. D Comparing the blood transcriptional responses between the source of infection groups for targeted pathways. For every gene, expression values were scaled across all sepsis samples. Then, for each source of infection, the vector of mean expression values was ordered for gene set enrichment analysis implementing 1000 permutations. For each selected pathway, we summarize its enrichment by magnitude, using the BH adjusted p value correcting for all existing Reactome database pathways, and direction using the normalized enrichment score (red = + ve, blue = −ve)
| The heterogeneity of the host response to sepsis makes stratification of patients into subgroups with more similar pathobiological profiles a major challenge. Our results suggest that the source of infection partly explains sepsis heterogeneity and should be taken into account when selecting patients for trials testing immune modulatory drugs. |